Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients With Post-COVID Syndrome

RegeneCyte (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.

Inclusion Criteria:1. Male or female aged ≥ 182. With post-COVID syndrome3. Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR or antigen test)4. Able to provide signed informed consent (by the subject or his/her legally authorized representative)5. Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consentExclusion Criteria:1. Neurological disorders prior to COVID-19 diagnosis2. With pre-existing terminal illness3. With known immune disease4. Is pregnant or breastfeeding5. Is currently participating in another investigational study or has been taking any other investigational product within the last 4 weeks before screening6. Has received any vaccination within 3 weeks prior to the first IP infusion7. Judged by the investigator to be not suitable for study participation8. Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters